As the P.R. machine kicks into gear to support the launch of Spravato/Esketamine, the first FDA approved Ketamine-derived treatment, Kevin Nicholson (President, CEO of Ketamine Wellness Centers) digs into the details that tend to receive less attention.

This episode focuses on the cost of Spravato to the provide, end user, and insurer:

- What are the preliminary cost estimates for Spravato (wholesale)

- Can we estimate the cost to the patient?

- Will insurance cover the drug?

- How will the treatment schedule effect the cost?

www.ketaminewellnesscenters.com/category/podcast/